Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study

Roger, 2012, Heart disease and stroke statistics—2012 update: a report from the American Heart Association, Circulation, 125, e2, 10.1161/CIR.0b013e31823ac046 Korean Statistical Information Service: Cost for medical treatment by disease. http://kosis.kr/abroad/abroad_03List.jsp?parentId=350_35001,A000. Accessed April 30, 2013. Whelton, 2004, Hypertension curriculum review: epidemiology and the prevention of hypertension, J Clin Hypertens, 6, 636, 10.1111/j.1524-6175.2004.03609.x Whitworth, 2003, World Health Organization International, Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension, J Hypertens, 21, 1983, 10.1097/00004872-200311000-00002 Pfizer Pharmaceuticals Co. NOVASC drug label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019787s053lbl.pdf. Accessed May 17, 2013. Novartis Pharmaceuticals Co. Diovan drug label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021283s035lbl.pdf. Accessed May 17, 2013. Frampton, 2009, Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension, Am J Cardiovasc Drugs, 9, 309, 10.2165/11201120-000000000-00000 Karpov, 2012, Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension, Adv Ther, 29, 134, 10.1007/s12325-011-0095-0 Exforge (amlodipine and valsartan) tablets. Prescribing information. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/exforge.pdf. Accessed April 30, 2013. 59th WMA General Assembly: WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. 2008. http://www.wma.net/en/30publications/10policies/b3. Accessed June 28, 2013. Korea Food and Drug Administration (KFDA): Korea good clinical practice (KGCP) guidelines. 2004. http://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do. Accessed June 28, 2013 Korea Food and Drug Administration (KFDA): Guidance of bioavailability and bioequivalence study. 2008. http://drug.mfds.go.kr/eBook/access/ecatalog_sp.jsp?callmode=&catimage=&Dir=37&cpage=1. Accessed June 28, 2013. Verbeeck, 2012, The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action, J Pharm Pharm Sci, 15, 376, 10.18433/J3VC8J Chow, 2009 Clinical Pharmacology Review. NDA 21-990, Exforge, Center for Drug Evaluation and Research, FDA. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021990s000_ClinPharmR.pdf. Accessed May17, 2013.